AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2018 Earnings Release
July 05 2018 - 4:15PM
Business Wire
AmerisourceBergen Corporation (NYSE: ABC) today announced that
it plans to release its results for the Third Quarter Fiscal 2018
on Thursday, August 2, 2018 prior to the opening of trading on the
New York Stock Exchange. The Company will host a conference call to
discuss the results at 8:30 a.m. ET on August 2, 2018.
Participating in the conference call will be:
Steven H. Collis, Chairman, President &
Chief Executive OfficerTim G. Guttman, Executive Vice President
& Chief Financial Officer
The dial-in number for the live call will be (612) 326-1011. No
access code is required. The live call will also be webcast via the
Company’s website at investor.amerisourcebergen.com. Users are
encouraged to log on to the webcast approximately 10 minutes in
advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and
webcast. A replay of the webcast will be posted on
investor.amerisourcebergen.com approximately two hours after the
completion of the call and will remain available for 30 days. The
telephone replay will also be available approximately two hours
after the completion of the call and will remain available for one
month. To access the telephone replay from within the U.S., dial
(800) 475-6701. From outside the U.S., dial (320) 365-3844. The
access code for the replay is 451454.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products,
value-driving services and business solutions that improve access
to care. Tens of thousands of healthcare providers, veterinary
practices and livestock producers trust us as their partner in the
pharmaceutical supply chain. Global manufacturers depend on us for
services that drive commercial success for their products. Through
our daily work—and powered by our 21,000 associates—we are united
in our responsibility to create healthier
futures. AmerisourceBergen is ranked #12 on the Fortune
500, with more than $150 billion in annual revenue. The
company is headquartered in Valley Forge, Pa. and has a
presence in 50+ countries. Learn more
at investor.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). Words such
as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,”
“should,” “can,” “project,” “intend,” “plan,” “continue,”
“sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,”
“anticipate,” “may,” “possible,” “assume,” variations of such
words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on
management’s current expectations and are subject to uncertainty
and change in circumstances. These statements are not guarantees of
future performance and are based on assumptions that could prove
incorrect or could cause actual results to vary materially from
those indicated. Among the factors that could cause actual results
to differ materially from those projected, anticipated, or implied
are the following: unfavorable trends in brand and generic
pharmaceutical pricing, including in rate or frequency of price
inflation or deflation; competition and industry consolidation of
both customers and suppliers resulting in increasing pressure to
reduce prices for the Company’s products and services; changes in
pharmaceutical market growth rates; changes in the United States
healthcare and regulatory environment, including changes that could
impact prescription drug reimbursement under Medicare and Medicaid;
increasing governmental regulations regarding the pharmaceutical
supply channel and pharmaceutical compounding; declining
reimbursement rates for pharmaceuticals; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; increased public concern over the abuse of opioid
medications; prosecution or suit by federal, state and other
governmental entities of alleged violations of laws and regulations
regarding controlled substances, and any related disputes,
including shareholder derivative lawsuits; increased federal
scrutiny and litigation, including qui tam litigation, for alleged
violations of laws and regulations governing the marketing, sale,
purchase and/or dispensing of pharmaceutical products or services,
and associated reserves and costs, including the reserve recorded
in connection with the proceedings with the United States
Attorney’s Office for the Eastern District of New York; material
adverse resolution of pending legal proceedings; the retention of
key customer or supplier relationships under less favorable
economics or the adverse resolution of any contract or other
dispute with customers or suppliers; changes to customer or
supplier payment terms; risks associated with the strategic,
long-term relationship between Walgreens Boots Alliance, Inc. and
the Company, including principally with respect to the
pharmaceutical distribution agreement and/or the global generic
purchasing services arrangement; changes in tax laws or legislative
initiatives that could adversely affect the Company’s tax positions
and/or the Company’s tax liabilities or adverse resolution of
challenges to the Company’s tax positions; regulatory action in
connection with the production, labeling or packaging of products
compounded by the Company’s compounded sterile preparations (CSP)
business; suspension of production of CSPs, including at our
Memphis 503B outsourcing facility; failure to realize the expected
benefits from the Company’s reorganization and other business
process initiatives; managing foreign expansion, including
non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and
regulations; declining economic conditions in the United States and
abroad; financial market volatility and disruption; substantial
defaults in payment, material reduction in purchases by or the
loss, bankruptcy or insolvency of a major customer; the loss,
bankruptcy or insolvency of a major supplier; changes to the
customer or supplier mix; malfunction, failure or breach of
sophisticated information systems to operate as designed; risks
generally associated with data privacy regulation and the
international transfer of personal data; natural disasters or other
unexpected events that affect the Company’s operations; the
impairment of goodwill or other intangible assets (including with
respect to foreign operations), resulting in a charge to earnings;
the acquisition of businesses that do not perform as expected, or
that are difficult to integrate or control, including the
integration of H. D. Smith and PharMEDium, or the inability to
capture all of the anticipated synergies related thereto or to
capture the anticipated synergies within the expected time period;
the effects of disruption from the transactions on the respective
businesses of the Company and H. D. Smith and the fact that the
transactions may make it more difficult to establish or maintain
relationships with employees, suppliers, customers and other
business partners; the disruption of the Company’s cash flow and
ability to return value to its stockholders in accordance with its
past practices; interest rate and foreign currency exchange rate
fluctuations; and other economic, business, competitive, legal,
tax, regulatory and/or operational factors affecting the Company’s
business generally. Certain additional factors that management
believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are
set forth (i) in Item 1A (Risk Factors) in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2017
and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180705005459/en/
AmerisourceBergen CorporationBennett MurphyVice
President, Investor
Relations610-727-3693bmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024